טוויטר \ NatureRevClinOncol בטוויטר: "MET inhibitor tepotinib, like capmatinib, seems to have good activity in METexon14-altered advanced-stage NSCLC #ASCO19 #LCSM https://t.co/qKqnwgzFo5"
Now Enrolling: VISION Clinical Trial: Advanced/Metastatic NSCLC With MET Alterations
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect
Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer
MET TKIs in METex14+ NSCLC: Tepotinib - Downloadable Slidesets - MET Inhibition in NSCLC - Oncology - Clinical Care Options
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Tepotinib for MET Exon 14 Skipping Mutations in NSCLC
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Therapeutics: tepotinib for lung cancer
Tepmetko (tepotinib) for the Treatment of Non-Small Cell Lung Cancer
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance | Future Oncology
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation - Takamori - 2021 - Thoracic Cancer - Wiley Online Library
Tepotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) – PRESENTATIONS | Merck
NICE recommends tepotinib as the first oral MET inhibitor treatment as an option for adult patients with advanced NSCLC with METex14 skipping alterations - ecan
The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram
In silico docking of: (a) tepotinib (8) and TC-E 5001 (2) in MET; (b)... | Download Scientific Diagram
c-Met inhibitor - Wikipedia
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy - Journal of Thoracic Oncology
Ivy Elkins on Twitter: "#Tepotinib in patient derived xenografts from #NSCLC brain metastases resulted in tumor regression, including complete responses. Potentially promising for patients with brain metastases with #METamp drivers. #AACR20 #lcsm @
IJMS | Free Full-Text | Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels
MET Inhibitors Active in Advanced NSCLC | MedPage Today
Tepotinib - Wikipedia
